Hologic, Inc. (NASDAQ:HOLX) Stake Trimmed by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. cut its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,894 shares of the medical equipment provider’s stock after selling 814 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Hologic were worth $281,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. General Partner Inc. acquired a new position in Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Raymond James reiterated an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Down 1.8 %

Shares of HOLX stock opened at $60.80 on Wednesday. The stock has a 50 day moving average of $65.70 and a 200-day moving average of $73.66. The firm has a market cap of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.